Diabetic Kidney Disease Clinical Trials 2023

What are the top hospitals conducting diabetic kidney disease research?

When it comes to advancing the treatment options for diabetic kidney disease, several top hospitals are leading the way. In Winston-Salem, Brookview Hills Research Associates, LLC is actively conducting two clinical trials focused on this condition. With a total of four trials dedicated to diabetic kidney disease since their first recorded trial in 2012, they have been making significant strides in understanding and combating this complex ailment. Moving across the country to Milwaukee, the Medical College of Wisconsin is also heavily involved in this area of research. They currently have two ongoing trials targeting diabetic kidney disease and have made substantial contributions with three completed studies thus far since initiating their first trial in 2022.

In Lawrenceville, Georgia Nephrology Research Institute has emerged as another key player in advancing our knowledge and treatments for diabetic kidney disease. Their commitment is evident through their participation in two active clinical trials focusing on this condition and three completed trials since recording their first study back in 2018.

Meanwhile, Brigham and Women's Hospital located in Boston has dedicated its resources to combatting diabetic kidney disease with two ongoing clinical trials that aim to improve outcomes for patients suffering from this debilitating condition. Since launching their initial trial alongside Brookview Hills Research Associates LLC back in 2012 or simultaneously as other institutions like Californiaf Wisconsin is also heavily involved in this area of research. They currently have two ongoing trials targeting diabetic kidney disease and have made substantial contributions with three completed studies thus far since initiating their first trial in 2022.

In Lawrenceville, Georgia Nephrology Research Institute has emerged as another key player in advancing our knowledge and treatments for diabetic kidney disease. Their commitment is evident through their participation in two active clinical trials focusing on this condition and three completed trials since recording their first study back in 2018.

Meanwhile, Brigham and Women's Hospital located in Boston has dedicated its resources to combatting diabetic kidney disease with two ongoing clinical trials that aim to improve outcomes for patients suffering from this debilitating condition. Since launching their initial trial alongside Brookview Hills Research Associates LLC back in 2012 or simultaneously as other institutions like California Institute of Renal Research situated at Chula Vista; which despite having comparatively lower numbers boasts an impressive count of five previously conducted investigations aiming towards alleviating complications related specifically due to kidneys associated with diabetes

These esteemed hospitals serve as beacons of hope for individuals affected by diabetic kidney disease while highlighting significant medical advancements happening throughout the United States. By working tirelessly on pioneering research initiatives aimed at better understanding and treating this devastating complication of diabetes, these institutions provide much-needed optimism for both current patients and future generations alike

Which are the best cities for diabetic kidney disease clinical trials?

Houston, Texas; Boston, Massachusetts; Aurora, Colorado; Lawrenceville, Georgia; and San Antonio, Texas are the top cities for diabetic kidney disease clinical trials. These cities offer a range of active trials investigating various treatment options such as INV-202 25 mg, Subcutaneous Bremelanotide, Atrasentan, canagliflozin, Fenofibrate, Pentoxifylline, Clinical Investigation and Renin-Angiotensin (RAAS) blockers in combination with Spironolactone among others. With their significant research efforts and multiple ongoing studies focused on combating diabetic kidney disease specifically these cities provide valuable opportunities for participating in cutting-edge clinical trials aiming to improve patient outcomes.

Which are the top treatments for diabetic kidney disease being explored in clinical trials?

Clinical trials exploring treatments for diabetic kidney disease have highlighted several promising options. Fenofibrate, an established medication, is currently undergoing one active trial and has been involved in a total of three clinical trials focused on diabetic kidney disease since its introduction in 2016. Another notable treatment under investigation is allogeneic adipose-derived mesenchymal stem cells (MSC) with a single infusion, which is being studied in one ongoing trial and was first listed as a potential therapy in 2021. Additionally, atrasentan is generating interest with one active trial and four past trials dedicated to diabetic kidney disease after being introduced back in 2011. These innovative approaches hold the possibility of transforming the landscape of treatment options for individuals suffering from this debilitating condition.

What are the most recent clinical trials for diabetic kidney disease?

Recent clinical trials have provided promising prospects for individuals with diabetic kidney disease, offering potential breakthroughs in treatment. Among these trials is the Renal Autologous Cell Therapy (REACT), a Phase 1 study aiming to utilize autologous cells as a therapeutic approach for diabetic kidney disease. Additionally, the Investigational Product - MIB 626 has exhibited encouraging results in its Phase 2 trial as a potential treatment option. Another notable trial examined the effectiveness of Subcutaneous Bremelanotide, showcasing its promise in mitigating the impact of diabetic kidney disease. Furthermore, INV-202 and canagliflozin have also shown positive outcomes during their respective Phase 2 studies. These recent advancements bring hope and optimism for improving the lives of those affected by this condition.

What diabetic kidney disease clinical trials were recently completed?

Several clinical trials investigating potential treatments for diabetic kidney disease have recently concluded, bringing hope to individuals affected by this condition. In April 2021, Boehringer Ingelheim successfully completed a trial evaluating the effectiveness of BI 685509. Similarly, CSL Behring wrapped up their study on CSL346 in September 2020. Furthermore, AstraZeneca completed a trial focusing on MEDI3506 in November 2019. These milestones signify significant progress in the pursuit of improved therapies for diabetic kidney disease and offer promise for patients dealing with its impact.